EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+39.94%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.39B
AUM Growth
+$3.39B
(+18%)
Cap. Flow
-$97.3M
Cap. Flow
% of AUM
-2.87%
Top 10 Holdings %
Top 10 Hldgs %
67.93%
Holding
88
New
8
Increased
10
Reduced
15
Closed
11
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$98.7M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$70.9M |
| 3 |
Gossamer Bio
GOSS
|
$49.8M |
| 4 |
Kymera Therapeutics
KYMR
|
$17.3M |
| 5 |
Sarepta Therapeutics
SRPT
|
$14.5M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$98.9M |
| 2 |
Revolution Medicines
RVMD
|
$48.8M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$48.7M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$43.5M |
| 5 |
argenx
ARGX
|
$37.9M |
Sector Composition
| 1 | Healthcare | 99.31% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $702M | 20.73% | 11,584,280 | – | – |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $354M | 10.45% | 5,183,431 | – | – |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $332M | 9.79% | 2,999,453 +131,308 | +5% | +$14.5M |
|
4
AnaptysBio
ANAB
$569M
| $192M | 5.66% | 7,521,024 | – | – |
|
5
Arvinas
ARVN
$568M
| $139M | 4.1% | 3,123,300 | – | – |
|
6
Xencor
XNCR
$580M
| $137M | 4.05% | 5,282,516 +100 | +0% | +$2.6K |
|
7
Galapagos
GLPG
$2.07B
| $136M | 4.02% | 3,197,500 | – | – |
|
|
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $112M | 3.3% | 3,951,566 | – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $98.7M | 2.91% | +3,460,208 | New | +$98.7M |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $98M | 2.89% | 5,991,479 | – | – |
|
11
Relay Therapeutics
RLAY
$619M
| $93.1M | 2.75% | 4,163,824 +440,283 | +12% | +$9.85M |
|
12
Kura Oncology
KURA
$686M
| $90.7M | 2.68% | 6,638,371 | – | – |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $70.9M | 2.09% | +1,015,572 | New | +$70.9M |
|
14
Zai Lab
ZLAB
$3.68B
| $69.4M | 2.05% | 2,030,252 -401,633 | -17% | -$13.7M |
|
|
15
Gossamer Bio
GOSS
$562M
| $49.8M | 1.47% | +4,160,887 | New | +$49.8M |
|
16
Allogene Therapeutics
ALLO
$251M
| $48.5M | 1.43% | 4,488,200 | – | – |
|
17
Avidity Biosciences
RNA
$5.99B
| $47.3M | 1.4% | 2,899,285 +139,780 | +5% | +$2.28M |
|
18
Design Therapeutics
DSGN
$315M
| $42.1M | 1.24% | 2,519,268 -114,910 | -4% | -$1.92M |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $39.1M | 1.15% | 285,793 -722,835 | -72% | -$98.9M |
|
20
Alector
ALEC
$238M
| $38.4M | 1.13% | 4,056,548 | – | – |
|
|
21
Revolution Medicines
RVMD
$7.1B
| $35.5M | 1.05% | 1,801,847 -2,476,222 | -58% | -$48.8M |
|
22
Atea Pharmaceuticals
AVIR
$267M
| $35.2M | 1.04% | 6,184,861 -155,778 | -2% | -$886K |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $34.4M | 1.01% | 3,493,194 +1,133,386 | +48% | +$11.2M |
|
|
TSVT
24
DELISTED
2seventy bio
TSVT
| $34.1M | 1.01% | 2,341,313 -1,154,630 | -33% | -$16.8M |
|
25
Nuvation Bio
NUVB
$1.02B
| $31.1M | 0.92% | 13,896,543 | – | – |
|